Key result
Extended pharmacoinvasive PCI shows similar 1-year mortality compared to primary PCI in STEMI.
Why the study?
When timely primary PCI is not feasible for STEMI, guidelines recommend a pharmacoinvasive strategy within 3-24 hours after fibrinolysis, but the role of PCI beyond 24 hours remains uncertain.
Does extended pharmacoinvasive PCI (3-48 hours after fibrinolysis) reduce mortality and complications compared to primary PCI in STEMI patients?
Observational (n=2,499)
Does extended pharmacoinvasive PCI (3-48 hours after fibrinolysis) reduce mortality and complications compared to primary PCI in STEMI patients?
Extended pharmacoinvasive PCI performed up to 48 hours after fibrinolysis yields clinical outcomes comparable to primary PCI, supporting an extended time window in resource-limited settings.
Answers are grounded in this paper and cite their sources.
Comparable mortality in this cohort should not yet change practice; leaves open the need for randomized trials in STEMI.
BACKGROUND In low- and middle-income countries, timely primary percutaneous coronary intervention (PPCI) for ST-elevation myocardial infarction (STEMI) is often limited. When timely PPCI is not feasible, current guidelines recommend a pharmacoinvasive strategy with routine angiography and PCI (if indicated) within 3-24 hours after fibrinolysis; however, the role of PCI beyond 24 hours remains uncertain. OBJECTIVES To compare clinical outcomes of PPCI versus extended pharmacoinvasive PCI (ePIPCI; PCI performed 3-48 hours after fibrinolysis) in STEMI. METHODS We analyzed the Madras Medical College STEMI Registry (September 2018-October 2019), comparing patients undergoing PPCI with those receiving ePIPCI, including subgroups treated at 3-24 and 24-48 hours after fibrinolysis. Outcomes included in-hospital complications, in-hospital mortality, and 1-year all-cause mortality. RESULTS Of 2,499 STEMI patients, 248 underwent PPCI and 210 ePIPCI; among the remainder, 1,091 (43.7%) received fibrinolysis only, 825 (33.0%) had no revascularization, and 125 (5.0%) underwent delayed PCI. In-hospital complications (23.0% vs 21.5%; RR 1.05, 95% CI 0.75-1.48; p=0.78), in-hospital mortality (4.4% vs 1.4%; RR 3.11, 95% CI 0.88-10.98; p=0.07), and 1-year mortality (8.5% vs 7.4%; RR 1.14, 95% CI 0.59-2.19; p=0.70) were similar between PPCI and ePIPCI. Outcomes were comparable between the 3-24-hour and 24-48-hour post-fibrinolysis subgroups. In multivariable analysis of the full cohort, index-hospitalization PCI was independently associated with lower in-hospital mortality (adjusted OR 0.36, 95% CI 0.21-0.62; p<0.001). In conclusion, PCI up to 48 hours after fibrinolysis yielded outcomes comparable to PPCI, supporting an extended pharmacoinvasive strategy in resource-limited settings.
No takes yet. Share an insight, caveat, or question.
Gnanaraj et al. (2026) conducted an observational in ST-elevation myocardial infarction (STEMI) (n=2,499). Extended pharmacoinvasive PCI (ePIPCI) vs. Primary PCI (PPCI) was evaluated on 1-year all-cause mortality (RR 1.14, 95% CI 0.59-2.19, p=0.70). Extended pharmacoinvasive PCI (3-48 hours post-fibrinolysis) resulted in similar 1-year mortality compared to primary PCI in STEMI patients.
Synapse has enriched 10 related papers. Consider them for comparative context: